Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$1.22
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-25.1M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$141M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-189.2%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-33.8M · FCF $-23.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-33.8M | $-33.8M | $-36.7M | $-28.1M | $-30.9M |
| EBITDA | $-34.2M | $-34.2M | $-39.9M | $-29.5M | $-41.1M |
| EPS | -0.39 | -0.39 | -0.51 | -0.44 | -0.49 |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Current Ratio | 4.39 | 4.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.9M | $-23.9M | $-25.1M | $-25.2M | $-27.3M |
| Returns | |||||
| ROE | -189.2% | -189.2% | -148.3% | -99.6% | -59.3% |
| Valuation | |||||
| P/B | 5.94 | 5.94 | 4.17 | 2.07 | 0.76 |
| Growth & Yield | |||||
| EPS Growth | 23.5% | 23.5% | -15.9% | 10.2% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.39
Residual
-2.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.